Admissions and Cost of Hospitalisation of Phenylketonuria: Spanish Claims Database Analysis

被引:4
作者
Darba, Josep [1 ]
Ascanio, Meritxell [2 ]
机构
[1] Univ Barcelona, Dept Econ, Diagonal 690, Barcelona 08034, Spain
[2] BCN Hlth Econ & Outcomes Res SL, Barcelona, Spain
关键词
NEWBORN SCREENING-PROGRAMS; INVESTIGATING TIME BURDEN; OUTCOMES;
D O I
10.1007/s40261-019-00760-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundPhenylketonuria is a well-known rare disease included in the neonatal screening of many countries. Therefore, there are few published data on the admissions and costs of phenylketonuria in Spain.ObjectiveThe objective of this study was to assess the number of admissions and the economic burden of phenylketonuria in Spain.MethodsPatients with phenylketonuria were identified from a Spanish database containing data from public and private healthcare centres from 1997 to 2015. The parameters obtained were characteristics of the patients, type of admissions, readmissions, discharges, length of stay, medical service, annual number of visits, annual number of patients, visit-associated costs and patient-associated costs.ResultsFive hundred and ninety-four patients with phenylketonuria were identified: 48.32% were male with a mean (standard deviation) age of 4.50 (10.23) years. The hospital admissions were divided into emergency visits (55.94%) and scheduled visits (43.92%). The majority of patients were discharged home (98.86%). The mean (standard deviation) duration of stay was 4.04 (4.98) days. The number of admissions per year rangedbetween 13 and 88, with an average of 1.18 admissions per patient per year. Finally, the mean cost per visit increased from Euro1064.91 to Euro3709.40, and the mean cost per patient increased from Euro1818.90 to Euro4239.32 from 1999 to 2015.ConclusionsThe access to economic and social data on phenylketonuria in Spain has been updated. The number of admissions in Spain between 1997 and 2015 and healthcare costs between 1999 and 2015 were calculated. There were 24 admissions as a result of a phenylketonuria diagnosis in 2015 and the mean healthcare cost per patient was Euro4239.32. This information can help to adapt and improve each healthcare system to take into consideration rare diseases.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 18 条
  • [1] Newborn screening 50 years later: access issues faced by adults with PKU
    Berry, Susan A.
    Brown, Christine
    Grant, Mitzie
    Greene, Carol L.
    Jurecki, Elaina
    Koch, Jean
    Moseley, Kathryn
    Suter, Ruth
    van Calcar, Sandra C.
    Wiles, Judy
    Cederbaum, Stephen
    [J]. GENETICS IN MEDICINE, 2013, 15 (08) : 591 - 599
  • [2] Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries
    Bosch, Annet M.
    Burlina, Alberto
    Cunningham, Amy
    Bettiol, Esther
    Moreau-Stucker, Flavie
    Koledova, Ekaterina
    Benmedjahed, Khadra
    Regnault, Antoine
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [3] Adverse medical outcomes of early newborn screening programs for phenylketonuria
    Brosco, Jeffrey P.
    Sanders, Lee M.
    Seider, Michael I.
    Dunn, Angela C.
    [J]. PEDIATRICS, 2008, 122 (01) : 192 - 197
  • [4] dos Santos LL, 2006, GENET MOL RES, V5, P33
  • [5] The time consuming nature of phenylketonuria: A cross-sectional study investigating time burden and costs of phenylketonuria in the Netherlands
    Eijgelshoven, Indra
    Demirdas, Serwet
    Smith, T. Alexander
    van Loon, Jeanni M. T.
    Latour, Sabine
    Bosch, Annet M.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2013, 109 (03) : 237 - 242
  • [6] The Prevalence of Phenylketonuria in Arab Countries, Turkey, and Iran: A Systematic Review
    El-Metwally, Ashraf
    Al-Ahaidib, Lujane Yousef
    Sunqurah, Alaa Ayman
    Al-Surimi, Khaled
    Househ, Mowafa
    Alshehri, Ali
    Da'ar, Omar B.
    Razzak, Hira Abdul
    AlOdaib, Ali Nasser
    [J]. BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [7] Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet
    Guest, J. F.
    Bai, J. J.
    Taylor, R. R.
    Sladkevicius, E.
    Lee, P. J.
    Lachmann, R. H.
    [J]. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2013, 57 (06) : 567 - 579
  • [8] HSIA DYY, 1970, LANCET, V2, P96
  • [9] The personal burden for caregivers of children with phenylketonuria: A cross-sectional study investigating time burden and costs in the UK
    MacDonald, Anita
    Smith, T. Alexander
    de Silva, Shamika
    Alam, Veronica
    van Loon, Jeanni M. T.
    [J]. MOLECULAR GENETICS AND METABOLISM REPORTS, 2016, 9 : 1 - 5
  • [10] Pitt James J, 2010, Clin Biochem Rev, V31, P57